Literature DB >> 32564332

Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice.

Tcs Costa1,2, E Fernandez-Villalba1, V Izura1, A M Lucas-Ochoa1, N J Menezes-Filho2, R C Santana3, M D de Oliveira2,4, F M Araújo1,2, C Estrada1, Vda Silva2, S L Costa5, M T Herrero6.   

Abstract

Inflammation is a predominant aspect of neurodegenerative diseases and experimental studies performed in animal models of Parkinson's disease (PD) suggesting that a sustained neuroinflammation exacerbates the nigrostriatal degeneration pathway. The central role of microglia in neuroinflammation has been studied as a target for potential neuroprotective drugs for PD, for example nonsteroidal anti-inflammatory drugs (NSAIDs) and matrix metalloproteinases (MMP) inhibitors that regulates microglial activation and migration. The aim of this study was to investigate the neuroprotective response of the iminosugar 1-deoxynojirimycin (1-DNJ) and compare its effect with a combined treatment with ibuprofen. MPTP-treated mice were orally dosed with ibuprofen and/or 1-DNJ 1. Open-field test was used to evaluate behavioral changes. Immunohistochemistry for dopaminergic neurons marker (TH+) and microglia markers (Iba-1+; CD68+) were used to investigate neuronal integrity and microglial activation in the substantia nigra pars compacta (SNpc). The pro-inflammatory cytokines TNF-α and IL-6 were analysed by qPCR. Treatments with either 1-DNJ or Ibuprofen alone did not reduce the damage induced by MPTP intoxication. However, combined treatment with 1-DNJ and ibuprofen prevents loss of mesencephalic dopaminergic neurons, decreases the number of CD68+/ Iba-1+ cells, the microglia/neurons interactions, and the pro-inflammatory cytokines, and improves behavioral changes when compared with MPTP-treated animals. In conclusion, these data demonstrate that the combined treatment with a MMPs inhibitor (1-DNJ) plus an anti-inflammatory drug (ibuprofen) has neuroprotective effects open for future therapeutic interventions. Graphical Abstract MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a protoxicant that, after crossing the Blood Brain Barrier, is metabolized by astrocytic MAO-B to MPDP+, a pyridinium intermediate, which undergoes further two-electron oxidation to yield the toxic metabolite MPP+ (methyl-phenyltetrahydropyridinium) that is then selectively transported into nigral neurons via the mesencephalic dopamine transporter. In this study, we demonstrated that MPTP induced death of dopaminergic neurons, microgliosis, increase of gliapses, motor impairment and neuroinflammation in mice, which were inhibited by combined 1-deoxynojirimycin and ibuprofen treatment.

Entities:  

Keywords:  Microgliosis; Neurodegeneration; Neuroinflammation; Parkinson’s disease; Phagocytosis

Mesh:

Substances:

Year:  2020        PMID: 32564332     DOI: 10.1007/s11481-020-09925-8

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  51 in total

1.  Persistent phagocytic characteristics of microglia in the substantia nigra of long-term Parkinsonian macaques.

Authors:  Carlos Barcia; Carmen María Ros; Francisco Ros-Bernal; Aurora Gómez; Valentina Annese; María Angeles Carrillo-de Sauvage; José Enrique Yuste; Carmen María Campuzano; Vicente de Pablos; Emiliano Fernández-Villalba; María Trinidad Herrero
Journal:  J Neuroimmunol       Date:  2013-06-05       Impact factor: 3.478

2.  Evidence of oligodendrogliosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism.

Authors:  V Annese; C Barcia; F Ros-Bernal; A Gómez; C M Ros; V De Pablos; E Fernández-Villalba; M E De Stefano; M-T Herrero
Journal:  Neuropathol Appl Neurobiol       Date:  2013-02       Impact factor: 8.090

3.  NSAID use and risk of Parkinson disease: a population-based case-control study.

Authors:  C Becker; S S Jick; C R Meier
Journal:  Eur J Neurol       Date:  2011-04-04       Impact factor: 6.089

4.  Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease.

Authors:  J R Boyle; E McDermott; M Crowther; A D Wills; P R Bell; M M Thompson
Journal:  J Vasc Surg       Date:  1998-02       Impact factor: 4.268

5.  Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism.

Authors:  V Annese; María-Trinidad Herrero; M Di Pentima; A Gomez; L Lombardi; C M Ros; V De Pablos; E Fernandez-Villalba; Maria Egle De Stefano
Journal:  Brain Struct Funct       Date:  2014-02-21       Impact factor: 3.270

6.  Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice.

Authors:  Laurel M Bolin; Iwona Strycharska-Orczyk; Richard Murray; J William Langston; Donato Di Monte
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

7.  Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.

Authors:  David L Brown; Kavita K Desai; Babak A Vakili; Chadi Nouneh; Hsi-Ming Lee; Lorne M Golub
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-02-12       Impact factor: 8.311

8.  IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease.

Authors:  C Barcia; C M Ros; V Annese; A Gómez; F Ros-Bernal; D Aguado-Yera; M E Martínez-Pagán; V de Pablos; E Fernandez-Villalba; M T Herrero
Journal:  Cell Death Dis       Date:  2011-04-07       Impact factor: 8.469

9.  ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo.

Authors:  Carlos Barcia; Carmen María Ros; Valentina Annese; María Angeles Carrillo-de Sauvage; Francisco Ros-Bernal; Aurora Gómez; José Enrique Yuste; Carmen María Campuzano; Vicente de Pablos; Emiliano Fernandez-Villalba; María Trinidad Herrero
Journal:  Sci Rep       Date:  2012-11-08       Impact factor: 4.379

10.  Microglial metabolic flexibility supports immune surveillance of the brain parenchyma.

Authors:  Louis-Philippe Bernier; Elisa M York; Alireza Kamyabi; Hyun B Choi; Nicholas L Weilinger; Brian A MacVicar
Journal:  Nat Commun       Date:  2020-03-25       Impact factor: 14.919

View more
  5 in total

1.  Aminochrome Induces Neuroinflammation and Dopaminergic Neuronal Loss: A New Preclinical Model to Find Anti-inflammatory and Neuroprotective Drugs for Parkinson's Disease.

Authors:  Fillipe Mendes De Araújo; Annyta Fernandes Frota; Lívia Bacelar de Jesus; Ticiane Caribe Macedo; Lorena Cuenca-Bermejo; Consuelo Sanchez-Rodrigo; Kariny Maria Silva Ferreira; Juciele Valéria Ribeiro de Oliveira; Maria de Fatima Dias Costa; Juan Segura-Aguilar; Silvia Lima Costa; Maria Trinidad Herrero; Victor Diógenes Amaral Silva
Journal:  Cell Mol Neurobiol       Date:  2022-01-06       Impact factor: 5.046

2.  Iminosugar Amino Acid idoBR1 Reduces Inflammatory Responses in Microglia.

Authors:  Olumayokun A Olajide; Victoria U Iwuanyanwu; Owolabi W Banjo; Atsushi Kato; Yana B Penkova; George W J Fleet; Robert J Nash
Journal:  Molecules       Date:  2022-05-23       Impact factor: 4.927

Review 3.  Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?

Authors:  Vidar Gundersen
Journal:  Front Neurosci       Date:  2021-02-25       Impact factor: 4.677

4.  Zonisamide Ameliorates Microglial Mitochondriopathy in Parkinson's Disease Models.

Authors:  Satoshi Tada; Mohammed E Choudhury; Madoka Kubo; Rina Ando; Junya Tanaka; Masahiro Nagai
Journal:  Brain Sci       Date:  2022-02-14

5.  Stereoselective Synthesis of Nojirimycin α-C-Glycosides from a Bicyclic Acyliminium Intermediate: A Convenient Entry to N,C-Biantennary Glycomimetics.

Authors:  Irene Herrera-González; Manuel González-Cuesta; M Isabel García-Moreno; José Manuel García Fernández; Carmen Ortiz Mellet
Journal:  ACS Omega       Date:  2022-06-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.